Hydroxychloroquine (HCQ) did not significantly reduce the incidence of COVID-19 among health care workers who participated in a national study that included Vanderbilt University Medical Center.
Originally developed to treat malaria, HCQ currently is prescribed as an anti-inflammatory medication to reduce the pain and swelling of rheumatoid arthritis and systemic lupus erythematosus (lupus).